drugset / Trial / NCT04470024

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

NCT04470024

Phase 1 Recruiting 56 enrolled Providence Health & Services
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.

Timeline

Start
2021-08-05
Primary completion
2027-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject DPV-001 Vaccine
Subject RAGIFILIMAB Monoclonal antibody
Subject Retifanlimab Monoclonal antibody

Indications